Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$40.6 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 43.44% year-over-year to -$40.6 million in Q2 2026; TTM through Jun 2026 was -$159.7 million, a 96.1% decrease from a year earlier, with the FY2025 full-year figure at -$124.0 million, up 4.63% from the prior year.
• Net Income towards Common Stockholders was -$40.6 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from -$40.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$14.2 million in Q3 2024, with the low at -$78.8 million in Q2 2024.
• Average Net Income towards Common Stockholders over 5 years is -$31.6 million, with a median of -$28.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 177.81% in 2024, then soared 64.11% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$34.1 million in 2022, then rose by 19.84% to -$27.3 million in 2023, then gained by 19.08% to -$22.1 million in 2024, then tumbled by 112.19% to -$46.9 million in 2025, then rose by 13.55% to -$40.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$40.6 million (Q2 2026), -$40.2 million (Q1 2026), and -$46.9 million (Q4 2025), per Business Quant data.